OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
Top Cited Papers
Open Access
- 24 March 2008
- journal article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 205 (4) , 825-839
- https://doi.org/10.1084/jem.20071341
Abstract
Regulatory T (T reg) cells are the major obstacle to cancer immunotherapy, and their depletion promptly induces conversion of peripheral precursors into T reg cells. We show that T reg cells can be functionally inactivated by OX40 triggering. In tumors, the vast majority of CD4(+) T cells are Foxp3(+) and OX40(bright). However, intratumor injection of the agonist anti-OX40 monoclonal antibody (mAb) OX86, but not anti-CD25 mAb, induces tumor rejection in 80% of mice, an effect that is abrogated by CD8 depletion. Upon intratumor OX40 triggering, increased numbers of infiltrating dendritic cells (DCs) migrate to draining lymph nodes and generate a new wave of tumor-specific cytotoxic T lymphocytes, as detected by tetramer and CD44 staining of node CD8(+) T lymphocytes. Tumor-bearing Rag1-knockout (KO) mice reconstituted with OX40-deficient T reg cells and wild-type (WT) effector T cells, or the reciprocal combination, showed that both T reg and effector T cells must be triggered via OX40 for the tumor to be rejected. Accordingly, WT but not OX40-KO mice receiving intratumor coinjection of OX86 and ovalbumin protein were able to revert tumor-induced tolerization of adoptively transferred OX40-competent OTII T lymphocytes. In conclusion, OX40-mediated inactivation of T reg cell function unleashes nearby DCs, allowing them to induce an adaptive immune response. In addition, the known OX40-dependent delivery of fitness signals to activated T cells is boosted by concurrent T reg cell inhibition. OX40 triggering thus has multiple effects that converge to mediate tumor rejection.Keywords
This publication has 61 references indexed in Scilit:
- OX40 costimulation turns off Foxp3+ TregsBlood, 2007
- CCR7 is required for the in vivo function of CD4+ CD25+ regulatory T cellsThe Journal of Experimental Medicine, 2007
- Regulatory T cells inhibit Fas ligand‐induced innate and adaptive tumour immunityEuropean Journal of Immunology, 2007
- Immunostimulatory monoclonal antibodies for cancer therapyNature Reviews Cancer, 2007
- Cancer despite immunosurveillance: immunoselection and immunosubversionNature Reviews Immunology, 2006
- Agonist Anti-GITR Antibody Enhances Vaccine-Induced CD8+ T-Cell Responses and Tumor ImmunityCancer Research, 2006
- Regulatory T cells, tumour immunity and immunotherapyNature Reviews Immunology, 2006
- Regulatory T cells inhibit stable contacts between CD4+ T cells and dendritic cells in vivoThe Journal of Experimental Medicine, 2006
- Triggering of OX40 (CD134) on CD4+CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITRBlood, 2005
- The Three Es of Cancer ImmunoeditingAnnual Review of Immunology, 2004